Cargando empresa
Scribe Therapeutics, Inc.
SCTX · Nasdaq · ·
23,01 US$+5,6 %cierre 29 sept
- 1M
- -19,1 %
SCTX · Nasdaq · ·
23,01 US$+5,6 %cierre 29 sept
Del propio 8-K de la empresa.
Scribe Therapeutics, Inc. no tiene ninguna transcripción de conferencia de resultados disponible.
“The second quarter and the weeks immediately following represented a transformational period for Scribe,”
Citado literalmente de la publicación, y mostrado solo cuando el informe lo atribuye a una persona con nombre.
Las publicaciones salen tras el cierre o antes de la apertura, así que el movimiento es el de la sesión siguiente.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com .
La propia descripción de la empresa, tal como aparece al pie de la publicación.
La cita y la descripción de la empresa proceden del 8-K del punto 2.02 que Scribe Therapeutics, Inc. presentó el 2 de septiembre de 2026; la tabla se elabora a partir de sus informes trimestrales. Leer la publicación en EDGAR Las cotizaciones están ajustadas por splits y dividendos.